# Deka Biosciences

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/deka-biosciences

- Industry: Biotechnology
- Headquarters: Germantown, US
- Website: www.dekabiosciences.com
- Total disclosed funding: $46M
- Latest round: Series B (Feb 6, 2023)
- Investors on record: 8

## About

Deka Biosciences, Inc., based in the US, focuses on developing advanced immunotherapy solutions, specifically through its innovative Diakine™ platform, designed for personalized treatment of inflammatory diseases and cancers.Deka Biosciences, Inc. specializes in immunotherapy solutions, leveraging its Diakine™ platform. Founded in 2018 and headquartered in Germantown, US, the company has undertaken strategic funding with two deals, the most recent being a Series B round in February 2023, raising USD 29.851 mn from lead investor MPM BioImpact and others. Pavel Khrimian, the founder, has a history of involvement in the biotech sector.Deka Biosciences specializes in innovative immunotherapy solutions through its core product offering, the Diakine™ platform. This next-generation cytokine therapy aims to provide personalized treatments for patients suffering from inflammatory diseases and cancer by leveraging unique immune responses. Diakine™ therapies integrate multiple cytokines, such as interleukin-4 and interleukin-10, in a single treatment to enhance therapeutic efficacy while targeting specific inflamed tissues and tumor antigens. The platform addresses significant unmet medical needs in areas such as Crohn’s disease, psoriasis, rheumatoid arthritis, and various cancers, serving healthcare providers, pharmaceutical partners, and ultimately the patients in North America and Europe.Deka Biosciences generates revenue through collaborations with other firms in the biopharmaceutical sector, focusing on B2B transactions with healthcare providers and research institutions. It engages in strategic partnerships to facilitate the development and commercialization of its Diakine™ therapies, which may include licensing agreements or co-development partnerships for clinical trials and product launches. The revenue model encompasses structures where partners share research and development costs while benefiting from the eventual sales of the resulting therapies, aligning with the goal of expanding market presence and access to treatment solutions.Deka Biosciences plans to utilize the recently raised USD 29.851 mn in Series B funding to support the development of its drug product manufacturing. The company aims to enhance its Diakine™ platform and looks to expand its presence in specific markets, particularly in North America and Europe, by developing new immunotherapy solutions that address various inflammatory diseases and cancers. Continued investment in product development is expected, facilitating a strategic pathway for future growth.

## Funding rounds

- Series B, Feb 6, 2023, $30M — Alexandria Venture Investments, MPM BioImpact, Echo Investment Capital, ATEM Capital, Leaps by Bayer, Plains Venture Partners, Viva BioInnovator, Lumira Ventures
- Series A, Oct 29, 2021, $16M — Alexandria Venture Investments, Echo Investment Capital, Leaps by Bayer, Viva BioInnovator, Lumira Ventures

## Investors

- Alexandria Venture Investments (https://capitalatlas.ai/funds/alexandria-venture-investments) — Series A, Series B
- Echo Investment Capital (https://capitalatlas.ai/funds/echo-investment-capital) — Series A, Series B
- Leaps by Bayer (https://capitalatlas.ai/funds/leaps-by-bayer) — Series A, Series B
- Viva BioInnovator (https://capitalatlas.ai/funds/viva-bioinnovator) — Series A, Series B
- Lumira Ventures (https://capitalatlas.ai/funds/lumira-ventures) — Series A, Series B
- MPM BioImpact (https://capitalatlas.ai/funds/mpm-bioimpact) — Series B
- ATEM Capital (https://capitalatlas.ai/funds/atem-capital) — Series B
- Plains Venture Partners (https://capitalatlas.ai/funds/plains-venture-partners) — Series B